v3.25.2
Operating Segment and Revenue Information
 12 Months Ended
Mar. 31, 2025
Disclosure of operating segments [abstract]  
Operating Segment and Revenue Information Operating Segment and Revenue Information
Takeda comprises a single operating segment and is engaged in the research, development, manufacturing, marketing and out-licensing of pharmaceutical products. This is consistent with how the financial information is viewed in allocating resources, measuring performance, and forecasting future periods by the CEO who is Takeda’s Chief Operating Decision Maker.
Disaggregation of Revenue Information
Takeda’s revenue from contracts with customers is comprised of the following:
Revenue by Type of Good or Service
JPY (millions)
For the Year Ended March 31
202320242025
Sales of pharmaceutical products
¥3,922,280 ¥4,163,652 ¥4,495,972 
Out-licensing and service income
105,198 100,110 85,579 
Total
¥4,027,478 ¥4,263,762 ¥4,581,551 
Revenue by Business Area and Product
JPY (millions)
For the Year Ended March 31
202320242025
Gastroenterology:
ENTYVIO¥702,744 ¥800,919 ¥914,098 
GATTEX/REVESTIVE93,076 119,252 146,289 
TAKECAB/VOCINTI (1)
108,719 118,526 130,763 
PANTOLOC/CONTROLOC (2)
45,518 46,495 44,591 
DEXILANT69,371 45,278 38,548 
EOHILIA
— 200 5,452 
Others75,113 85,538 77,282 
Total Gastroenterology 1,094,541 1,216,207 1,357,022 
Rare Diseases:
TAKHZYRO151,800 178,677 223,163 
ADVATE118,188 122,911 111,758 
ELAPRASE85,321 91,561 97,243 
REPLAGAL66,741 73,553 77,852 
ADYNOVATE/ADYNOVI66,553 66,308 64,613 
VPRIV48,372 51,295 53,457 
LIVTENCITY10,501 19,085 32,997 
ADZYNMA
— 425 7,082 
Others92,298 84,607 84,650 
Total Rare Diseases
639,774 688,423 752,816 
PDT:
Immunoglobulin
522,211 644,587 757,771 
Albumin
121,446 133,990 141,381 
Others121,702 125,123 133,510 
Total PDT
765,359 903,699 1,032,662 
JPY (millions)
For the Year Ended March 31
202320242025
Oncology:
ADCETRIS83,937 109,425 129,025 
LEUPLIN/ENANTONE111,311 107,350 119,265 
NINLARO92,691 87,361 91,242 
ICLUSIG47,206 54,706 70,728 
FRUZAQLA
— 10,080 47,954 
ALUNBRIG
20,556 28,524 36,432 
Others83,042 64,915 65,783 
Total Oncology438,742 462,362 560,430 
Vaccines:
QDENGA
144 9,557 35,580
Others
78,521 40,798 19,832 
Total Vaccines
78,664 50,355 55,412 
Neuroscience:
VYVANSE/ELVANSE459,289 423,221 350,607 
TRINTELLIX100,081 104,797 125,735 
ADDERALL XR
28,594 41,756 28,430 
Others49,747 57,241 61,044 
Total Neuroscience637,711 627,014 565,816 
Other:
AZILVA(1)
72,897 33,636 11,808 
FOSRENOL13,532 13,529 7,911 
Others
286,256 268,536 237,673 
Total Other
372,685 315,701 257,392 
Total¥4,027,478 ¥4,263,762 ¥4,581,551 
(1) The figures include the amounts of fixed dose combinations and blister packs.
(2) Generic name: pantoprazole
Geographic Information
Takeda’s revenue from contracts with customers is based in the following geographic locations:
JPY (millions)
For the Year Ended March 31
202320242025
Japan¥512,043 ¥451,391 ¥418,462 
U.S.2,103,772 2,195,711 2,379,651 
Europe and Canada842,668 966,835 1,055,252 
Latin America
160,375 198,100 235,848 
China
150,973 174,844 191,740 
Asia (excluding Japan & China)74,033 86,375 99,392 
Russia/CIS88,431 72,594 72,356 
Other95,182 117,911 128,849 
Total¥4,027,478 ¥4,263,762 ¥4,581,551 
“Other” includes the Middle East, Oceania and Africa. This disaggregation provides revenue attributable to countries or regions based on the customer location.
Takeda’s non-current assets are held in the following geographic locations:
JPY (millions)
As of March 31
20242025
Japan
¥366,276 ¥317,089 
U.S.
8,223,949 7,654,971 
Ireland885,496 872,944 
Switzerland
860,795 799,783 
Other1,361,811 1,330,348 
Total¥11,698,327 ¥10,975,135 
Non-current assets exclude financial instruments, deferred tax assets and net defined benefit assets.
Information Related to Major Customers
During the year ended March 31, 2023, Cencora, Inc. (previously called “AmerisourceBergen Corporation”) and its subsidiaries (collectively, “Cencora Group”), McKesson Corporation and its subsidiaries (collectively, “McKesson Group”) and Cardinal Health, Inc. and its subsidiaries (collectively, “Cardinal Health Group”) represented more than 10% of Takeda’s sales. The sales to Cencora Group, McKesson Group and Cardinal Health Group were JPY 575,294 million, JPY 540,356 million and JPY 424,527 million, respectively, for the year ended March 31, 2023.
During the year ended March 31, 2024, Cencora Group, McKesson Group and Cardinal Health Group, represented more than 10% of Takeda’s sales. The sales to Cencora Group, McKesson Group and Cardinal Health Group were JPY 579,065 million, JPY 578,767 million and JPY 436,951 million, respectively, for the year ended March 31, 2024.
During the year ended March 31, 2025, McKesson Group and Cencora Group represented more than 10% of Takeda’s sales. The sales to McKesson Group and Cencora Group were JPY 592,323million and JPY 577,017million, respectively, for the year ended March 31, 2025.
Other Revenue Information
Contract Balances
JPY (millions)
As of March 31
20242025
Receivables from contracts with customers
Trade receivables (Note 17)
¥612,439 ¥651,414 
Contract assets
Unbilled receivables
2,574 1,372 
Contract liabilities
Deferred income (Note 24)
8,259 23,547 
Advance payments
45 64 
Takeda’s contract assets relate to the right to receive consideration where performance was completed based on the contract, and trade receivables are recognized when the right to receive consideration becomes unconditional.
Takeda’s contract liabilities primarily relate to out-licensing arrangements or product purchase and supply agreements where Takeda receives cash consideration prior to the completion of its performance obligations under the agreements. The revenue recognized during the years ended March 31, 2023, 2024, and 2025 that was included in the contract liability balance as of the beginning of the year was JPY 49,319 million, JPY 5,526 million, and JPY 5,634 million, respectively. The revenue recognized during the years ended March 31, 2023, 2024, and 2025 from performance obligations satisfied (or partially satisfied) in previous periods was JPY 79,251 million, JPY 80,794 million, and JPY 97,560 million, respectively, and primarily relates to royalty income.
Transaction price allocated to the remaining performance obligations
JPY (millions)
Total
Duration of the remaining performance obligations
Within one year
Between one and five years
More than five years
Contract liabilities as of March 31, 2024
¥8,304 ¥6,119 ¥517 ¥1,668 
Contract liabilities as of March 31, 2025
23,611 21,781 526 1,304